Formulary Watch |

Prime Therapeutics Removes Perforomist from Medicare Formulary

Pfizer Recalls More Lots of its Smoking Cessation Drug Chantix

A total of 16 lots have been recalled.

Merck’s Welireg Cleared for Rare Tumors

Blue Cross of Massachusetts to Change Pharmacy Providers

Effective January 2023, the organization will switch from Express Scripts to CVS Caremark.

FDA Approves Pfizer’s Ticovac

This vaccine protects against tick-borne encephalitis in people over the age of 1 year.

CMS Provides Billing Code for Pepaxto

The multiple myeloma therapy now has a permanent J code under Medicare Part B.

FDA Approves Lyumjev for Use with Insulin Pump

Trials result show that Lyumjev compares favorably to Humalog.

Study: Utilization Management Efforts Add Billions to Health Care Costs

Drug Shortages Update

FDA Approves Generic of Chantix, Pfizer's Smoking Cessation Drug

Study: Veltassa Lowers Overall Health Care Costs

Express Scripts Releases List of 2022 Formulary Exclusions

Veterans Administration Declines Coverage for Aduhelm

GoodRx, Boehringer Ingelheim Partner on Savings Program for Top Meds

FDA Issues CRL for FibroGen’s Roxadustat

The decision follows an advisory committee recommendation not to approve because of safety issues.

NSCLC Drug Trial Stopped Early After Strong Survival Results

FDA Accepts NDA for Dermavant’s Tapinarof

Second Specialty Pharmacy Chosen to Dispense Rezurock

The graft-versus-host disease therapy has also been added to NCCN Guidelines.

Psoriasis Drug Skyrizi is Now Available as a Single Injection

Previously patients administered as two, 75-mg shots. Now they can inject a single 150-mg dose.

Counterfeit Versions of Biktarvy and Descovy Found in Pharmacies

The bottles have a counterfeit foil seal or label and contain an incorrect number of tablets.

Formulary Watch: Drug Shortages, August 8, 2021

KVK Tech Recalls Two Lots of Atovaquone

The therapy for HIV-related pneumonia was exposed to cold weather during shipment.

Regeneron’s COVID-19 Cocktail Snags Expanded EUA Indication

Exelixis Submits Cabometyx for Thyroid Cancer

The PDUFA date has been set for December 4, 2021; FDA has designated this as a Priority Review.

FDA Grants Keytruda Priority Review for Melanoma

The PDUFA date for this indication is December 4, 2021.

ParaPRO’s Antiparasitic Natroba is Now Available

FDA Grants Tecentriq Priority Review for NSCLC

BMS Pulls Lymphoma Indication for Istodax

The therapy had received accelerated approval in 2011 but a phase 3 confirmatory trial found it did not meet the end point of progression-free survival.

Texas Medicaid Changes Formulary Status of Endari

FDA Approves AstraZeneca Lupus Drug